Fiduciary Alliance LLC Buys 23,152 Shares of Pfizer Inc. $PFE

Fiduciary Alliance LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 168,415 shares of the biopharmaceutical company’s stock after acquiring an additional 23,152 shares during the quarter. Fiduciary Alliance LLC’s holdings in Pfizer were worth $4,194,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Pfizer in the 4th quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $29,000. Darwin Wealth Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $32,000. Finally, True Wealth Design LLC grew its position in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks highlights Pfizer’s deep and diversified oncology portfolio and pipeline, which could support longer-term revenue growth and investor sentiment ahead of quarterly results. How Pfizer’s Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: MarketWatch noted Pfizer stock rose Wednesday (while still underperforming the broader market), signaling intermittent buying interest that can counterbalance downside pressure from analyst moves. Pfizer Inc. stock rises Wednesday, still underperforms market
• Neutral Sentiment: Pfizer invited shareholders to a virtual Annual Meeting on April 23, 2026 — a standard corporate governance event that may include Q&A but is unlikely to move the stock materially by itself. Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
• Neutral Sentiment: ResearchAndMarkets published a biopharmaceutical CXO market report that cites major players including Pfizer; this industry-level report highlights outsourcing and supply-chain trends but has indirect impact on Pfizer’s near-term stock moves. $1.05 Bn Biopharmaceutical CXO Markets – Global Forecast Report 2026-2032
• Neutral Sentiment: Pfizer Limited announced a special window for dematerialisation of physical shares (local/regulatory matter) — relevant to regional investors but not material to NYSE-listed PFE’s valuation. Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
• Neutral Sentiment: Pfizer CEO Albert Bourla commented on U.S./European academic competitiveness vs. China — a strategic/PR item reflecting management views on R&D policy rather than an immediate stock catalyst. Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change
• Negative Sentiment: Bank of America cut its price target on PFE from $27 to $26 and set a Neutral rating — this reduces upside expectations and can apply downward pressure on the stock. Benzinga
• Negative Sentiment: RBC Capital reaffirmed a Sell rating on Pfizer, reinforcing bearish analyst sentiment and adding to near-term selling pressure from income-oriented or risk-averse investors. RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
• Negative Sentiment: Yahoo Finance ran a piece explaining why Pfizer shares tumbled earlier in the week — investors should read it for details on the drivers of recent volatility (analyst moves, trading flows or company-specific news). Why Pfizer Stock Tumbled on Tuesday

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. TD Cowen reiterated a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.10.

Pfizer Trading Down 0.9%

NYSE PFE opened at $27.23 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a twelve month low of $21.08 and a twelve month high of $28.75. The firm has a market capitalization of $154.84 billion, a PE ratio of 20.02 and a beta of 0.43. The stock’s 50 day moving average is $27.19 and its 200 day moving average is $25.91.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the company posted $0.63 earnings per share. The firm’s revenue was down 1.2% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.